We are live on ! Find out more
LYRA

LYRA THERAPEUTICS INC

Delisted

LYRA was delisted on the 16th of March, 2026.

78 hedge funds and large institutions have $283M invested in LYRA THERAPEUTICS INC in 2024 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 29 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

23,225% more call options, than puts

Call options by funds: $1.87M | Put options by funds: $8K

257% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 7

142% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 12

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

30% more funds holding

Funds holding: 6078 (+18)

28% more capital invested

Capital invested by funds: $222M → $283M (+$61.4M)

0.09% less ownership

Funds ownership: 1.61%1.53% (-0.09%)

Holders
78
Holders Change
+18
Holders Change %
+30%
% of All Funds
1.12%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
25
Increased
29
Reduced
12
Closed
7
Calls
$1.87M
Puts
$8K
Net Calls
+$1.86M
Net Calls Change
+$616K
Name Holding Trade Value Shares
Change
Change in
Stake
PA
1
Perceptive Advisors
New York
$79.4M
Citadel Advisors
2
Citadel Advisors
Florida
$27M +$7.88M +29,557 +52%
NCM
3
Nantahala Capital Management
Connecticut
$17.5M -$6.55M -24,584 -30%
SB
4
Samsara BioCapital
California
$17.3M
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$17.1M -$1.37M -5,151 -9%
VA
6
VR Adviser
New York
$16M +$2.66K +10 +0%
Vanguard Group
7
Vanguard Group
Pennsylvania
$9.21M +$2.19M +8,201 +38%
PVI
8
Pura Vida Investments
New York
$8.79M
RA
9
Rosalind Advisors
Ontario, Canada
$7.12M -$3.97M -14,884 -39%
IC
10
Ikarian Capital
Texas
$6.57M -$1.05M -3,951 -16%
ABG
11
Ally Bridge Group
New York
$6.24M +$5.35M +20,075 New
TLP
12
Tri Locum Partners
New York
$6.09M +$5.22M +19,576 New
VPC
13
Vestal Point Capital
New York
$4.98M -$11.7M -44,000 -73%
Verition Fund Management
14
Verition Fund Management
Connecticut
$4.78M +$4.09M +15,364 New
LCM
15
Laurion Capital Management
New York
$4.65M +$3.76M +14,109 +1,664%
WP
16
Woodline Partners
California
$4.21M +$408K +1,531 +13%
PHP
17
Parkman Healthcare Partners
Connecticut
$3.99M -$600K -2,253 -15%
Ensign Peak Advisors
18
Ensign Peak Advisors
Utah
$3.68M +$1.54M +5,795 +96%
Invesco
19
Invesco
Georgia
$3.45M +$2.96M +11,105 New
Walleye Capital
20
Walleye Capital
New York
$3.28M +$2.73M +10,262 +3,421%
Millennium Management
21
Millennium Management
New York
$2.53M +$427K +1,602 +25%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$2.24M +$123K +460 +7%
SSA
23
Schonfeld Strategic Advisors
New York
$2.22M +$1.68M +6,312 +757%
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$2.14M +$447K +1,678 +32%
Goldman Sachs
25
Goldman Sachs
New York
$2.08M +$1.71M +6,432 +2,464%

LYRA Hedge Fund Activity: Q1 2024 in Review

78 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in LYRA THERAPEUTICS INC (LYRA) for Q1 2024, worth a combined $283M — up 28% from $222M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new LYRA positions and 7 closed out — a net gain of 18 holders — while 29 added to existing stakes and 12 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $7.88M. The largest seller was Vestal Point Capital, cutting an estimated $11.7M.

  • 78 institutional investors held LYRA THERAPEUTICS INC (LYRA) as of Q1 2024, up from 60 in Q4 2023.
  • Funds reported $283M of LYRA THERAPEUTICS INC stock for Q1 2024, up 28% quarter-over-quarter.
  • 25 funds opened new LYRA THERAPEUTICS INC positions in Q1 2024 and 7 closed out, a net change of +18 holders.
  • The largest LYRA THERAPEUTICS INC buyer in Q1 2024 was Citadel Advisors, an estimated $7.88M added.
  • The largest LYRA THERAPEUTICS INC seller in Q1 2024 was Vestal Point Capital, an estimated $11.7M sold.

Based on aggregated 13F filings for Q1 2024.